Navigation Links
DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments
Date:3/31/2009

he Company's website at www.dorbiopharma.com.

This press release contains forward-looking statements that reflect DOR BioPharma, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec(R), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014 Research and ... Exome Sequencing Market by Product, by Services, by Technology, by ... offering. Whole Exome Sequencing (WES) is next-generation ... genome, i.e. the exon. The exome, which is the total ... the total genome and is actually converted into proteins after ...
(Date:9/15/2014)... 15. September 2014 Die zweite jährliche ... vom 12. bis 18. Oktober stattfinden. Die IPAW ... Therapeutics Association (PPTA) und ihrer Mitgliedsunternehmen ... Das globale Bewusstsein für die Gewinnung von Quellplasma ... beim Retten und Verbessern von Leben zu würdigen ...
(Date:9/15/2014)... Md. , Sept. 15, 2014  The second ... be celebrated October 12-18. A joint initiative of the ... member companies , IPAW is designed to: ... , Recognize the contributions of plasma donors in ... lifesaving plasma protein therapies and rare diseases ...
(Date:9/14/2014)... regulate protein functions in a wide variety of ways, ... a protein can take on another form and perform ... that fold wrongly can cause serious diseases such as ... also have a tendency to "infect" other molecules of ... fibrils or plaques. These amyloids can damage cells and ...
Breaking Biology Technology:Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3Measuring modified protein structures 2Measuring modified protein structures 3
... is now licensed to supply ISBT 128-compliant label,design and printing software ... ... and laboratories, MILWAUKEE, Aug. 28 Niceware(R) International, LLC is,excited ... to provide ISBT 128-compliant blood bag labeling,software solutions that support ISBT ...
... August 28 XTL Biopharmaceuticals,Ltd. (NASDAQ: XTLB ... in the acquisition, development and commercialization of,therapeutics for ... and hepatitis C, today announced the receipt on ... indicating that, according to the,Company,s financial statements for ...
... its ADR Listing to the NASDAQ Capital Market, ... (NASDAQ: XTLB ; LSE: XTL; TASE: XTL), ... commercialization of,therapeutics for the treatment of unmet medical ... the receipt on August 23,2007, of a NASDAQ ...
Cached Biology Technology:Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software 2XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market 2XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market 3XTL Receives Staff Letter From NASDAQ 2XTL Receives Staff Letter From NASDAQ 3
(Date:9/15/2014)... tropical rainforest teeming with life it,s not what comes ... the first time evidence of Doncaster,s 310-million-year-old past, including a ... mining tip. , Some of the fossilised plants and creatures ... the egg case, several horseshoe crabs and some previously unrecorded ... preserved in rocks that formed within the coal and shale ...
(Date:9/15/2014)... , , , ... , , , , ... own set of symptoms. The finding could be a first... , , ... , , , , ... , , , , , , , New research shows that schizophrenia ...
(Date:9/15/2014)... SANTA BARBARA, Calif. , Sept. 15, 2014 ... Goleta, California , announces the public ... has a very unique, patented product, combining room ... GENiSYSS is the only company to make personal ... Photo - http://photos.prnewswire.com/prnh/20140912/145664   Photo ...
Breaking Biology News(10 mins):'Jaws' lived in Doncaster 2Schizophrenia not a single disease but multiple genetically distinct disorders 2Schizophrenia not a single disease but multiple genetically distinct disorders 3Schizophrenia not a single disease but multiple genetically distinct disorders 4Schizophrenia not a single disease but multiple genetically distinct disorders 5GENiSYSS Launches Website about Easy, Inexpensive Home DNA Storage for Everyone 2
... Scientists at Barrow Neurological Institute have recently made discoveries about ... central nervous system (CNS) a finding that could have ... multiple sclerosis. The research, led by Barrow,s Fu-Dong Shi, MD, ... Journal of Experimental Medicine , and simultaneously highlighted in ...
... The availability of highly nutritious forage is one of ... in western Oregon and Washington, according to a modeling ... Service,s Pacific Northwest (PNW) Research Station. Findings from the ... planning for the ecologically and economically important ungulate in ...
... Researchers at the Swedish medical university Karolinska Institutet have been ... receptor that binds sperm at the beginning of fertilization. The ... to better understanding of infertility and may enable entirely new ... has been grasped by the encounter of gametes egg ...
Cached Biology News:Modeling study identifies characteristics of high elk-use areas in western Oregon, Washington 2
... iLink makes it easy to supply microplates, ... Developed with operator convenience in mind, iLink ... ease of use. The iLink software is ... assays or sub-assays, that can be copied ...
... integrated digital microscope and camera system that ... optical adjustment or software installation. Built on ... combines simplicity and advanced technology for users ... viewing of a macro image and a ...
... DASGIP Overhead Drive for individual and ... for flexible agitation of DASGIP vessels, featuring ... impellers. ,Up to 16 overhead drives ... DASGIP Cultivation Systems fedbatch-pro® and cellferm-pro® for ...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
Biology Products: